Skip to main content

Table 2 Characteristics and treatment outcomes by model of ART delivery

From: Similar costs and outcomes for differentiated service delivery models for HIV treatment in Uganda

Sample characteristics (n, % unless otherwise specified)

FBIM

(n = 128)

CCLAD

(n = 131)

CDDP

(n = 132)

FBG1 /2

(n = 129, 115)a

FDR

(n = 133)

Total

(n = 653)

Sex (female)

82 (64%)

92 (70%)

95 (72%)

129 (100%)

75 (56%)

473 (72%)

Age, years (median, IQR)*

41 (34–51)

44 (40–49)

44 (38–52)

29 (25–34)

44 (35–51)

41 (33–48)

Duration on ART, years (median, IQR)*

3 (2–5)

5 (2–8)

7 (5–10)

2 (1–3)

8 (5–10)

5 (2–8)

Duration in DSDM, years (median, IQR)b

3 (2–5)c

1 (1–1)

1 (1–6)

1 (1–1)

2 (1–4)

1 (1–3)

Clients on first-line regimens b

117 (91%)

124 (95%)

121 (92%)

120 (93%)

111 (83%)

593 (91%)

Clients on second-line regimens b

11 (9%)

7 (5%)

11 (8%)

9 (7%)

22 (17%)

60 (9%)

Baseline CD4 count, cells/µl (median,

IQR)d

Unrecorded CD4 count

310 (199–430)

19 (15%)

221 (128–353)

16 (12%)

210 (143–328)

6 (5%)

433 (250–629)

39 (30%) a

234 (118–349)

3 (2%)

272 (152–414)

84 (13%)

Outcomes at 12 months

      

Retained in care

126 (98%)

127 (97%)

130 (98%)

120 (93%)

133 (100%)

636 (97%)

Unsuppressed (viral load > 1000 copies/ml)

12 (9.4%)

4 (3.1%)

3 (2.3%)

6 (4.7%)

4 (3%)

29 (4.5%)

Suppressed (viral load < 1000 copies/ml)

110 (86%)

125 (95%)

123 (93%)

115 (89%)

118 (89%)

591 (91%)

Unknown viral status

6 (5%)

2 (2%)

1 (1%)

8 (6%)

11 (9%)

28 (4.3%)

Outcomes at 24 months

      

Retained in caree

122 (97%)

127 (98%)

132 (100%)

110 (96%)

131 (99%)

622 (98%)

Unsuppressed viral load (> 1000 copies/ml)

10 (7.9%)

2 (1.5%)

3 (2.3%)

4 (3.5%)

3 (3%)

22 (3.5%)

Suppressed viral load (< 1000 copies/ml)

111 (88%)

117 (90%)

121 (92%)

108 (94%)

119 (90%)

576 (91%)

Unknown viral status

5 (4%)

11 (9%)

8 (7%)

3 (3%)

10 (8%)

37 (6%)

  1. a Sample characteristics and 12-month outcomes are for the FBG1 cohort; 24 month outcomes are for the FBG2 cohort. The characteristics of persons in each FBG sample were very similar. In the FBG2 sample, all clients had a recorded baseline CD4 count, while in FBG1 30% did not
  2. b Age, duration on ART, duration on DSDM and regimen are measured at the time of enrollment in the study (January 2017)
  3. c For FBIM, the duration on DSDM is equivalent to the duration on ART. Some clients switched from their DSDM back to FBIM when becoming unsuppressed, but they were retained in their original models for purposes of analysis
  4. d Baseline CD4 count at time of ART initiation. Data missing for < 10% of clients in all models
  5. e Not retained in care (in 2nd year period) included one death (FBIM); the rest were lost to follow-up (LTFU).
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us